Sarcoma Metastatic Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting sarcoma metastatic clinical trials across 4 countries. Studies span Phase 2, Phase 1, Not Applicable. Top locations include Beijing, China, Besançon, Bourgogne-Franche-Comté, France, Charlotte, North Carolina, United States. Updated daily from ClinicalTrials.gov.


Sarcoma Metastatic Trials at a Glance

7 actively recruiting trials for sarcoma metastatic are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Beijing, Besançon, and Charlotte. Lead sponsors running sarcoma metastatic studies include Essen Biotech, Milton S. Hershey Medical Center, and Centre Oscar Lambret.

Browse sarcoma metastatic trials by phase

Treatments under study

About Sarcoma Metastatic Clinical Trials

Looking for clinical trials for Sarcoma Metastatic? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Sarcoma Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Sarcoma Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

OsteosarcomaEwing SarcomaEwing Sarcoma Metastatic
Milton S. Hershey Medical Center406 enrolled2 locationsNCT07321912
Recruiting
Phase 2

Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma

Angiosarcoma Metastatic
Sun Yat-sen University69 enrolled1 locationNCT04859465
Recruiting
Not Applicable

Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.

Sarcoma MetastaticLocally Advanced Soft Tissue Sarcoma
Centre Oscar Lambret377 enrolled11 locationsNCT06211257
Recruiting
Phase 1Phase 2

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

OsteosarcomaOsteosarcoma Metastatic
Peking University People's Hospital56 enrolled1 locationNCT07479732
Recruiting
Phase 2

Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Sarcoma,Soft TissueSarcoma Metastatic
Wake Forest University Health Sciences50 enrolled2 locationsNCT07291297
Recruiting
Phase 2

Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients

Angiosarcoma of SkinAngiosarcoma Metastatic
National Cancer Center, Japan38 enrolled5 locationsNCT06673628
Recruiting
Phase 1Phase 2

Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas

SarcomaSarcoma, SynovialSarcoma,Soft Tissue+6 more
Essen Biotech60 enrolled1 locationNCT07066982